A detailed history of Ubs Group Ag transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 625,719 shares of DYN stock, worth $18.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
625,719
Previous 243,929 156.52%
Holding current value
$18.6 Million
Previous $8.61 Million 161.09%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$31.94 - $47.04 $12.2 Million - $18 Million
381,790 Added 156.52%
625,719 $22.5 Million
Q2 2024

Aug 13, 2024

BUY
$23.65 - $35.63 $250,737 - $377,749
10,602 Added 4.54%
243,929 $8.61 Million
Q1 2024

May 13, 2024

BUY
$13.06 - $29.18 $1.43 Million - $3.19 Million
109,277 Added 88.09%
233,327 $6.62 Million
Q4 2023

Feb 09, 2024

BUY
$6.62 - $13.64 $462,685 - $953,326
69,892 Added 129.05%
124,050 $1.65 Million
Q3 2023

Nov 09, 2023

BUY
$8.6 - $12.18 $271,665 - $384,754
31,589 Added 139.97%
54,158 $485,000
Q2 2023

Aug 11, 2023

BUY
$8.53 - $14.28 $180,153 - $301,593
21,120 Added 1457.56%
22,569 $253,000
Q1 2023

May 12, 2023

SELL
$10.88 - $15.0 $88,421 - $121,905
-8,127 Reduced 84.87%
1,449 $16,000
Q4 2022

Feb 08, 2023

BUY
$9.37 - $13.8 $79,926 - $117,714
8,530 Added 815.49%
9,576 $110,000
Q3 2022

Nov 10, 2022

BUY
$7.2 - $15.17 $115 - $242
16 Added 1.55%
1,046 $13,000
Q2 2022

Aug 10, 2022

SELL
$4.36 - $10.5 $39,859 - $95,991
-9,142 Reduced 89.87%
1,030 $7,000
Q1 2022

May 16, 2022

BUY
$6.52 - $12.27 $63,635 - $119,755
9,760 Added 2368.93%
10,172 $98,000
Q4 2021

Feb 14, 2022

BUY
$11.89 - $16.07 $4,601 - $6,219
387 Added 1548.0%
412 $5,000
Q3 2021

Nov 15, 2021

BUY
$15.6 - $21.46 $390 - $536
25 New
25 $0
Q2 2021

Aug 13, 2021

SELL
$15.94 - $22.33 $52,251 - $73,197
-3,278 Closed
0 $0
Q1 2021

May 12, 2021

SELL
$14.0 - $29.3 $93,548 - $195,782
-6,682 Reduced 67.09%
3,278 $51,000
Q4 2020

Feb 11, 2021

BUY
$16.81 - $23.94 $167,427 - $238,442
9,960 New
9,960 $209,000

Others Institutions Holding DYN

About Dyne Therapeutics, Inc.


  • Ticker DYN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,765,400
  • Market Cap $1.54B
  • Description
  • Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...
More about DYN
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.